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BACKGROUND: This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45mg 6-month depot
formulation in 151 men with prostate cancer who received 2 intramuscular injections administered 24 weeks apart.
METHODS: The primary efficacy measurement was the proportion of patients achieving suppression of serum testosterone
to p50ngdl
 1 from week 4 through week 48. Adverse events (AEs) and hormonal and safety laboratory values were
monitored.
RESULTS: The primary efficacy end point was achieved in 93.4% of subjects (95% confidence interval (89.2%, 97.6%)).
There were nine escapes from testosterone suppression during the study, none of which were accompanied by a rise in PSA.
By week 4, mean testosterone concentration was suppressed below castrate levels to 15.9ngdl
 1; suppression was
maintained for the entire 24-week duration of each depot injection. No mean increase in testosterone was observed after the
second injection. Mean PSA levels were maintained below 3ngml
 1 from week 14 through the 48-week treatment period. The
most frequent AE was flushing (58.3%). Injection site reactions were reported in 24.5% of patients.
CONCLUSIONS: Leuprolide acetate 45mg 6-month depot demonstrated rapid and sustained testosterone suppression
through 12 months and was well tolerated. This 6-month leuprolide acetate depot will decrease the number of annual
injections in the treatment of prostate cancer.
Prostate Cancer and Prostatic Diseases (2012) 15, 93–99; doi:10.1038/pcan.2011.50; published online 25 October 2011
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Introduction
Prostate cancer is the second most frequently diag-
nosed cancer among men in the United States, and
estimates predict that approximately 217730 new cases
were diagnosed in 2010.
1 For patients with metastatic
prostate cancer and locally advanced disease, androgen
deprivation therapy is the mainstay of treatment, and
can be achieved through the use of gonadotropin-
releasing hormone agonists (GnRHa) or bilateral
orchiectomy.
2–4
Leuprolide acetate is a GnRHa, which is widely used
for the treatment of hormone-dependent conditions
in men and women. A chronic administration of
GnRHa leads to downregulation of GnRH receptors in
the pituitary gland, which results in a complete
suppression of luteinizing hormone (LH), follicle-stimu-
lating hormone and gonadal steroids after an initial
stimulatory phase (hormonal flare). Usually, within
4 weeks of initiation of leuprolide acetate therapy, serum
testosterone is reduced to near surgically castrated
levels.
5–7 Leuprolide acetate 3- and 4-month depot
formulations are frequently used for the treatment of
advanced prostate cancer. This new 6-month depot
formulation of leuprolide acetate was developed to
provide an additional treatment option for prostate
cancer patients, which reduces the number of injections
needed to maintain effective testosterone suppression to
two per year.
This study evaluated the efficacy and safety of two
formulations (A and B) of leuprolide acetate 6-month
depot 45mg in men with prostate cancer using a
sequential study design. The primary efficacy end
point was the proportion of patients who achieved
suppression of serum testosterone to p50ngdl
 1 from
week 4 through week 48.
Only formulation A met prespecified criteria for
efficacy and the results of this part of the study are
reported herein. Formulation B demonstrated a higher
mean initial plasma drug concentration with a lower
plasma concentration at the end of the injection period.
More subjects escaped from testosterone suppression,
and this part of the study was prematurely terminated.
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Materials and methods
Study design
This open-label clinical trial was conducted from
February 2008 to June 2009 at 39 sites in the United
States. The study consisted of a screening period (up to
28 days), a 12-month (48-week) treatment period and a
30-day follow-up period. Subjects received two intra-
muscular injections of leuprolide acetate 6-month depot
administered 6 months (24 weeks) apart. Study drug was
supplied in a prefilled, dual chamber syringe that
contained sterile lyophilized powder and diluent, which
were mixed just before injection.
Subjects
Male subjects, 18 years or older, with histologically
confirmed prostate cancer (National Cancer Institute
(NCI) stages 2–4), or rising PSA following either radical
prostatectomy (X0.2ngml
 1 increase from previous test
on two consecutive assessments) or prostate irradiation
(X2.0ngml
 1 increase above the nadir) were included.
Subjects had a prestudy serum testosterone level of
4150ngdl, an Eastern Cooperative Oncology Group
performance score of p2, a life expectancy of at least
18 months, and at least 32 weeks had elapsed since
prior hormone therapy. Patients were discontinued from
the study if serum testosterone was not maintained at
therapeutic levels. Institutional review board approval
was obtained at each site and written informed consent
was provided by each subject before screening or any
study-related procedures.
Efficacy end points
The primary efficacy end point was the suppression of
serum testosterone to p50ngdl
 1 from week 4 through
week 48. The prespecified secondary efficacy end points
were the change from baseline in PSA concentrations at
study visits, the mean testosterone concentration at each
treatment visit and ‘acute-on-chronic’ changes in testos-
terone and LH concentrations from just before the second
(week 24) injection through the visit 14 days after the
second injection. A post hoc analysis examined the
incidence of PSA recurrence defined as a PSA X5ngml
 1
and an increase in PSA of 50% compared with nadir.
Hormonal assays
Efficacy measurements during treatment included the
assessment of LH and testosterone at visits on days 1, 2
and 8 and at weeks 2, 4, 8, 14, 20 and 24 and again after
the second injection on day 169 and at days 170, 171 and
176 and at weeks 26, 30, 34, 40, 46 and 48. PSA was
measured at days 1 and 8 and weeks 14, 24, 25, 30, 40 and
48. Serum testosterone was measured using liquid
chromatography with mass spectrometry detection after
extraction (lower limit of quantitation¼2.5–3ngdl
 1)b y
Esoterix (Calabasas Hills, CA, USA) and Abbott Bioana-
lysis (Abbott Park, IL, USA). Serum LH was measured
by immunochemiluminometric assay (lower limit of
quantitation¼0.02mIUml
 1) by Esoterix. PSA was
measured by a chemiluminescent immunoassay (Access
Hybritech PSA; lower limit of quantitation¼
0.01ngml
 1) by Esoterix.
Safety
Safety assessments included evaluation of adverse events
(AEs) and vital signs at all visits, and clinical laboratory
tests at most visits. The injection site was monitored
closely for signs of reaction by the clinical investigator for
up to 2 weeks following each depot injection.
Statistics
All efficacy analyses were performed on the intent-to-
treat population, which included those subjects who
received at least 1 dose of study drug and who did not
have anti-androgen usage during the first 32 days of
study drug. Based on a regulatory request, the primary
efficacy analysis was adjusted to censor those four
subjects who received an anti-androgen after day 32 at
the last testosterone value before use of the anti-
androgen. One additional subject was censored, due to
a laboratory error, at the last measurement before the
error. Both the results from the adjusted and prespecified
results are reported. Both of these primary efficacy
analyses did not include prematurely discontinued
subjects whose final testosterone value was measured
before day 19 and was not suppressed, as week 4
suppression could not be determined. The percentage
and 90% 2-sided confidence interval (CI) of subjects
suppressed for the primary efficacy end point were
calculated using a Kaplan–Meier method for right-
censored observations, as were the percentages and CI
for the subgroups. The prespecified requirement for
efficacy was that the lower limit of the 2-sided 90% CI
for suppression had to be X87%. Tests of pairwise
comparisons between subgroups were based on Z
statistics using the Kaplan–Meier estimates and their
standard errors.
Summary statistics were generated for the serum
testosterone and PSA concentrations at each treatment
visit, and ‘acute-on-chronic’ changes in testosterone and
LH concentrations. For subjects with PSA 44ngml
 1 at
baseline, the number and percentage who achieved a
PSA value p4ngml
 1 were calculated. The percentage
of subjects with X50% increase in PSA from nadir and
PSA X5ngml
 1 was also calculated.
AEs were summarized by the percentage of sub-
jects with events during treatment coded by the
MedDRA dictionary (version 11.1; http://www.ich.org/
products/meddra.html). Injection site reactions that
were assessed by the investigator to be AEs were
reviewed via an accumulation of all associated terms.
Change from baseline in safety laboratory and the
percentages of subjects with laboratory values meeting
predefined potentially clinically significant thresholds
were summarized.
Results
A total of 151 subjects enrolled and received at least
1 dose of study drug and 134 subjects (88.7%) completed
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adjusted and prespecified primary efficacy end point
analyses. Subject demographics and baseline character-
istics are presented in Table 1.
Serum testosterone
For the adjusted primary end point, serum testosterone
was suppressed to p50ngdl
 1 from week 4 through
week 48 in 93.4% of subjects (95% CI (89.2%, 97.6%)).
The 90% CI was (89.9%, 96.9%) so the lower limit of the
2-sided 90% CI exceeded the prespecified minimum
(87%) for efficacy (Table 2). For the prespecified end
point, serum testosterone was suppressed to p50ngdl
 1
from week 4 through week 48 in 93.6% of subjects
(90% CI (90.2%, 97.0%)). For the nine subjects who did
not have successful suppression of testosterone by each
primary end point analysis, one subject failed to achieve
suppression by day 32, three subjects escaped suppres-
sion just before the second injection and five subjects
escaped suppression after the second injection. Of the
five subjects who escaped suppression after the second
injection, three subjects experienced a transient increase
in testosterone within 2 weeks of the second injection
(‘acute-on-chronic’ reaction), one subject escaped on
study day 211 and the remaining subject escaped at the
end of the second treatment cycle. Notably, most (5/8)
testosterone escapes were transient, and none were
associated with increases in PSA. Of the eight escapes,
four occurred in patients who were African-American.
Subgroup analyses of testosterone suppression by NCI
prostate cancer stage based on tumor node metastasis,
body mass index and race were performed and the
results are presented in Table 3. The suppression rate
was numerically higher for Caucasian subjects than for
African-American subjects, but the difference was not
statistically significant (P¼0.179). The only significant
difference was between those subjects with stage IV
prostate cancer vs those subjects with stage II prostate
cancer, with the subjects with more advanced prostate
cancer (stage IV) having a higher rate of response to
treatment (100 vs 91.8%, P¼0.003).
After a transient hormonal flare reaction after the first
injection, treatment with leuprolide acetate suppressed
mean serum testosterone to below castrate levels for the
entire 24-week duration of each depot injection
(Figure 2a). At baseline, mean serum testosterone
concentration was 434.6ngdl
 1, but decreased to sup-
pression levels as early as week 4 (15.9ngdl
 1) and
remained p11ngdl
 1 at the end of each treatment cycle.
Similarly, after initial stimulation after the first injection,
LH was suppressed for the 24-week interval following
each depot injection (Figure 2b).
‘Acute-on-chronic’ response
Small, but statistically significant, mean increases in
serum LH levels (0.1–0.2mIUml
 1) were observed from
just before the second injection on week 24 to serial time
points within 2 weeks after the second injection (‘acute-
on-chronic’ reaction). In contrast, small mean decreases
(0.0–2.0ngdl
 1) in testosterone levels were observed
even though three subjects experienced transient tes-
tosterone escapes during the ‘acute-on-chronic’ phase.
Serum PSA
Mean serum PSA concentrations through the 48-week
treatment period are shown in Figure 3. At baseline, 75%
of subjects (112/149) had serum PSA concentrations that
were 44ngml
 1. Similar to testosterone, there was a
transient rise in mean serum PSA concentrations after
the first injection. Within 14 weeks of treatment, 87.4%
(97/111) of those subjects with elevated PSA levels at
baseline achieved a PSA p4ngml
 1. At all subsequent
visits, at least 86% of subjects with a baseline PSA
44ngml
 1 had PSAvalues p4ngml
 1. The incidence of
PSA recurrence was low, castration-resistant prostate
cancer occurred in only 4.6% of subjects (7/151).
Safety
Treatment-emergent AEs were reported for 94.7% of
subjects during the treatment period; the majority of AEs
were mild to moderate in severity (Table 4). AEs of
injection site reaction were reported in 37 subjects
(24.5%), including injection site pain in 27 subjects
(17.9%), injection site discomfort and injection site
erythema each in 3 subjects (2.0%) and injection site
hematoma and injection site swelling in 2 subjects each
(1.3%). All were mild or moderate in severity, and none
led to discontinuation of study drug.
151 Enrolled/Included in Safety
Population 
148 Included in Adjusted Primary
Efficacy Analysis and Primary
Efficacy Analysis (ITT)
a
17 Discontinued Study Participation
b
7  Adverse Events
5  Withdrew Consent
1  Protocol Violation
1  Insufficient Therapeutic Response
1  Disease Progression
2  Other
134 Completed Study
Figure 1 Subject disposition. Flow of subjects through the trial.
aThree patients had no testosterone value for week 4 and were excluded fron
the intent-to-treat (ITT) population for the primary efficacy endpoint, 5 subjects were censored in the adjusted primary endpoint;
bsubject
accountability determined by investigator.
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fracture, diabetes and cardiac events were of interest
because of their possible association with androgen
deprivation therapy. Ten subjects had AEs of anemia or
decreased hemoglobin. Two of these AEs were consid-
ered serious, and the subjects received blood transfu-
sions, but these events were considered not related
to study drug by the investigator (alternative etiologies
of suspected subacute upper gastrointestinal bleeding
and metastatic cancer). Only 2 of the 10 AEs of anemia
or decreased hemoglobin were considered treatment
related. No subjects prematurely discontinued due to an
AE of anemia. Five subjects experienced bone fractures
as a result of falls or other trauma, but only one event
was considered possibly related to study drug, and
no subjects discontinued from the study due to an AE
related to bone fractures. A total of eight subjects
experienced AEs that were related to diabetes mellitus
(n¼2), increases in serum glucose (n¼5) or hypoglyce-
mia (n¼1), which included one report of non-related
new onset diabetes and only one possibly related event
(increase in serum glucose).
Overall, a high proportion of subjects (88.1%) had a
history of cardiovascular disease. One or more
cardiac events were reported for 18 subjects. Ten
subjects experienced serious cardiac AEs, all of whom
had medical histories with significant risk factors
(for example, hypertension, coronary artery disease and
hypercholesterolemia). One subject prematurely discon-
tinued the study due to worsening coronary artery
disease, weakness and hyperkalemia. A total of four
treatment-related AEs were reported in three subjects:
angina pectoris, tachycardia and mitral valve incompe-
tence and tricuspid valve incompetence.
Overall, the incidence of sexual dysfunction during
the study, reported as AEs, was low. One patient
each reported reduced libido or loss of libido, and
two patients reported erectile dysfunction.
Serious AEs were reported for 31 subjects (20.5%),
including one death that was not considered related to
Table 1 Subject demographics and baseline characteristics
Characteristic ITT population for
primary efficacy end
point (N¼148)
Race, n (%)
White 116 (78.4)
Black or African-American 30 (20.3)
Asian 1 (0.7)
Multi race 1 (0.7)
Ethnicity
Not Hispanic or Latino 141 (95.3)
Age, n (%)
X65 years 131 (88.5)
Age, years
Mean±s.d. 74.9±8.42
Median (range) 76.0 (48.0–92.0)
Weight, kg
Mean±s.d. 85.1±13.95
Median (range) 84.0 (49.0–129.4)
Height, cm
Mean±s.d. 175.3±7.24
Median (range) 175.3 (149.9–193.0)
BMI, kgm
 2
Mean±s.d. 27.7±4.20
Median (range) 27.3 (18.0–41.5)
Time since first histological diagnosis of prostate cancer (N¼147)
Mean±s.d. 4.6±4.7
Range 0.0–19.6
Prostate cancer staging (N¼142), n (%)
II 101 (71.1)
III 20 (14.1)
IV 21 (14.8)
Testosterone, ngdl
 1
Mean±s.d. 433.0±175.12
Median (range) 401.0 (114.0–1060.0)
LH, mIUml
 1
Mean±s.d. 7.2±6.54
Median (range) 5.6 (0.1–45.0)
PSA (N¼146), ngml
 1
Mean±s.d. 35.7±138.22
Median (range) 10.0 (0.2–1517.3)
Gleason score category (N¼142), n (%)
4 3 (2.1)
5 1 (0.7)
6 45 (31.7)
7 53 (37.3)
8 28 (19.7)
9 12 (8.5)
Abbreviations: BMI, body mass index; ITT, intent-to-treat; LH, luteinizing
hormone.
Table 2 Suppression of serum testosterone from week 4 through
week 48
a
N Percent suppressed
b s.e. Two-sided 90% CI
148 93.4% 2.13% 89.9%, 96.9%
Abbreviation: CI, confidence interval.
aAdjusted primary end point.
bSuppression of testosterone occurred by study day 32 and with no escape
through week 48.
Table 3 Suppression of serum testosterone by subgroups of
prostate cancer stage, BMI and race
Subgroup N Percent
suppressed
a
(%)
s.e.
(%)
Two-sided
90% CI
NCI stage
Stage II 101 91.8 2.8 87.2%, 96.4%
Stage III 20 94.1 5.7 84.7%, 100.0%
Stage IV 21 100.0 0.0 100.0%, 100.0%
BMI, kgm
 2
o25 44 95.0 3.5 89.3%, 100.0%
X25 to o30 67 92.3 3.3 86.9%, 97.8%
X30 37 94.4 3.8 88.2%, 100.0%
Race
Caucasian 116 95.4 2.0 92.1%, 98.7%
African-American 30 86.5 6.3 76.2%, 96.8%
Other 2 100.0 0.0 100.0%, 100.0%
Abbreviations: BMI, body mass index; CI, confidence interval;
NCI, National Cancer Institute.
aSuppression of testosterone from week 4 through week 48 based on
prespecified analysis.
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old, had a history of chronic obstructive pulmonary
disease, and died as the result of a treatment-emergent
AE of aspiration pneumonia that began 11 days after he
completed the study. Two subjects had serious AEs that
were considered possibly related to study drug: colonic
pseudo-obstruction in one and angina pectoris in one.
Both serious AEs resolved, and the subjects completed
the study. Two subjects had serious AEs that resulted in
discontinuation from the study: coronary artery disease,
asthenia and hyperkalemia in one and non-Hodgkins
lymphoma stage IV in one.
Glucose
At baseline, the mean fasting blood glucose concentra-
tion was above normal (5.8mmoll
 1) and further
increased by 0.4±1.8mmoll
 1 at the final treatment
visit. However, only one subject, who had a history of
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Figure 2 Mean testosterone levels (a) and mean luteinizing hormone (LH) concentrations (b) during the treatment period. The dashed line
in (a) represents castrate levels for serum testosterone (50ngdl
 1). Time points for administration of leuprolide acetate 6-month depot
injections are indicated in both panels.
Figure 3 Mean PSA levels during the treatment period. Time points
for administration of leuprolide acetate 6-month depot injections
are indicated.
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potentially clinically significant (X16.6mmoll
 1) during
the treatment period.
Hemoglobin
Mean hemoglobin values decreased through the first
14 weeks of treatment and then were stable through the
end of the treatment period, with a mean decrease of
1.05±1.01gdl
 1 at the final treatment visit. All other
laboratory changes were unremarkable and consistent
with the study population.
Discussion
This study evaluated the efficacy and safety of a new
6-month depot formulation of leuprolide acetate and
demonstrated that testosterone suppression to and below
castration levels (p50ngdl
 1) was rapid and sustained
throughout the 12-month (48-week) treatment period;
93.4% of subjects had castrate levels of serum testoster-
one from week 4 through week 48. None of the escapes
from testosterone suppression were associated with
increases in PSA.
The suppression of testosterone achieved with this
leuprolide acetate 6-month depot formulation is consis-
tent with that achieved with the leuprolide acetate 3- and
4-month depot formulations.
6,7 A cross-study compar-
ison, using the simple percentage of subjects who did not
achieve testosterone suppression to p50ngdl
 1 by week
4 or escaped from suppression on or before week 48,
indicated that the leuprolide acetate 6-month depot
formulation is at least as efficacious as the marketed
3- and 4-month depot formulations (failure rates of
6.0, 10.3 and 10.9% for 6-month, 3-month and 4-month
formulations, respectively).
6,7
Overall, subgroup analyses indicate that leuprolide
acetate 6-month depot was effective for testosterone
suppression regardless of prostate cancer stage, body
mass index or race. In the total population, treatment
with leuprolide acetate 6-month depot elicited a statis-
tically significantly higher rate of response in the patients
with the most advanced disease (P¼0.003, stage IV vs
stage II). However, while not statistically significant,
there was a numerical difference in the percentage of
African-American men with testosterone suppression
(86.5%) compared with Caucasian men (95.4%). The
reasons for this difference are unclear.
With leuprolide acetate 6-month depot treatment,
mean testosterone levels after week 4 were suppressed
below 15ngdl
 1 for the remainder of the 48-week
treatment period and were p11ngdl
 1 at the end
of each treatment cycle. In this study, the use of
anti-androgens was excluded per protocol because use
of these drugs would interfere with assessment of
hormonal response (such as the primary end point)
and potentially with the effects of leuprolide acetate on
testosterone suppression during the initial phase of
treatment. In our study, mean testosterone increases
were not observed with the second leuprolide acetate
injection. Small mean decreases in testosterone were
observed from before the second injection to serial time
points after the injection, and only three individual
subjects experienced increases above 50ngdl
 1, indicat-
ing that suppression of testosterone remained stable even
after repeated exposure to leuprolide acetate 6-month
depot in the vast majority of patients. In addition, PSA
levels, which are used as a surrogate marker for prostate
cancer progression, paralleled the decreases in testoster-
one concentrations, and only 4.6% of subjects experi-
enced PSA recurrence, which occurred without an
increase in serum testosterone.
Leuprolide acetate 6-month depot was well tolerated,
and the type and incidence of AEs and laboratory
findings reported were consistent with the safety profiles
of the marketed leuprolide acetate intramuscular 3- and
4-month depot formulations
6,7 and a marketed subcuta-
neous 6-month depot formulation,
8 as expected for this
patient population.
7–9 Overall, the incidence of injection
site reactions was 24.5%, which is higher than reported
in other studies with 6-month depot formulations of
GnRHa.
8,10,11 The rigorous monitoring for injection site
reactions may have increased the frequency of adverse
reaction reporting in our study population. The relatively
low incidence of sexual side effects, which were collected
as AEs, might be due to under reporting of these events
in this study.
The mean changes in glucose and hemoglobin
observed in this study were consistent with the mean
changes observed for the marketed leuprolide acetate
3- and 4-month depot formulations.
7,9 Androgen depri-
vation therapy has been shown to increase insulin
resistance and increase the risk of new onset
diabetes.
12–15 Notably, there was only one potentially
Table 4 Incidence and severity of treatment-emergent AEs
(X5% of subjects)
Adverse event
a Leuprolide acetate 45mg
6-month depot (N¼151)
All
events,
n (%)
Severity
b
Mild Moderate Severe
Hot flush 88 (58.3) 58 23 7
Injection site pain 27 (17.9) 22 5 0
Fatigue 18 (11.9) 15 2 1
Constipation 15 (9.9) 9 6 0
Arthralgia 14 (9.3) 8 6 0
Insomnia 13 (8.6) 12 1 0
Headache 11 (7.3) 6 4 1
Cough 10 (6.6) 7 3 0
Hematuria 10 (6.6) 7 3 0
Nasopharyngitis 10 (6.6) 6 4 0
Dysuria 9 (6.0) 7 2 0
Hypertension 9 (6.0) 3 6 0
Rash 9 (6.0) 8 1 0
Anemia 8 (5.3) 6 1 1
Back pain 8 (5.3) 4 4 0
Chronic obstructive
pulmonary disease
8 (5.3) 3 2 3
Dizziness 8 (5.3) 6 2 0
Musculoskeletal pain 8 (5.3) 7 1 0
Nocturia 8 (5.3) 5 3 0
Upper respiratory tract infection 8 (5.3) 4 4 0
Urinary tract infection 8 (5.3) 4 3 1
Abbreviation: AEs, adverse events.
aCoded using MedDRA 12.0 Preferred Term.
bSubjects were counted for most severe event, as assessed by the investigator,
for each preferred term.
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established diabetes and only one report of new onset
diabetes during this study. Reductions in hemoglobin are
known to occur after orchiectomy and GnRHa therapy
as a result of loss of androgen stimulation of the
hematopoietic system.
16–18
This study demonstrates the efficacy and safety of the
leuprolide acetate 6-month depot formulation for sus-
tained reduction of serum testosterone to castrate levels
in men with locally advanced and advanced prostate
cancer. The availability of a leuprolide acetate 6-month
depot formulation will limit the number of injections
needed per year to two, and better align with the
treatment schedules of prostate cancer patients, which
may improve patient compliance and outcomes.
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